Synthesis and activity of arylcoumarin derivatives with therapeutic effects on diabetic nephropathy

In the literature, daidzein has been reported to exhibit cardiovascular protective effects and hypoglycemic activity in mice. We sought to design and synthesize a novel compound, SJ-6, an analog of daidzein, with improved hypoglycemic properties. Although SJ-6 demonstrated favorable hypoglycemic effects, its pharmacokinetic limitations prompted us to design and synthesize prodrugs of SJ-6. We conducted a comprehensive evaluation of the prodrugs, including in vitro and in vivo studies, such as cytotoxicity, absorption, distribution, metabolism, excretion, and toxicity (ADMET) simulation analysis, in vitro blood-brain barrier (BBB) permeability evaluation, compound effect on insulin resistance, oral glucose tolerance test (OGTT), in vivo plasma concentration testing, acute toxicity test in rats, and long-term gavage administration experiment. Furthermore, we examined the antidiabetic nephropathy activity of our lead compound, compound 10, which demonstrated superior efficacy compared with the positive control drug, metformin hydrochloride. Our findings suggest that compound 10 represents a promising lead compound for the prevention and treatment of diabetic nephropathy. The synthesis of coumarin derivatives and their antidiabetic nephropathy (anti-DN) activities are reported. Among them, compound 10 alleviated insulin resistance, reduced creatinine, urea nitrogen, and triglyceride levels in DN rats, and alleviated renal and aortic injuries in DN rats.image

Automated summary

Daidzein analog SJ-6 showed favorable hypoglycemic effects, but its pharmacokinetic limitations led to the synthesis of prodrugs. Compound 10 exhibited superior anti-diabetic nephropathy activity and promising potential for prevention and treatment.